Adamis Pharmaceuticals

Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
15 (est)
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
300 11682 El Camino Real

Adamis Pharmaceuticals Data and Metrics

Adamis Pharmaceuticals Financial Metrics

USD

Net income (FY, 2015)

(13.6 m)

EBIT (FY, 2015)

(13.9 m)

Market capitalization (27-Jun-2017)

137.8 m

Closing share price (27-Jun-2017)

5.2

Cash (31-Dec-2015)

4.1 m
Adamis Pharmaceuticals's current market capitalization is $137.8 m.
USDFY, 2014FY, 2015

EBIT

(4.4 m)(13.9 m)

Net Income

(8.2 m)(13.6 m)
USDFY, 2014FY, 2015

Cash

5.4 m4.1 m

Inventories

14.5 k71 k

Current Assets

4.2 m

Total Assets

15.1 m12.1 m

Accounts Payable

671 k497.8 k

Additional Paid-in Capital

58.3 m78.3 m

Retained Earnings

(46.1 m)(69 m)

Total Equity

9.3 m

Financial Leverage

1.3 x
USDFY, 2014FY, 2015

Depreciation and Amortization

888.4 k

Inventories

14.5 k(165 k)

Accounts Payable

671 k116 k

Cash From Operating Activities

5.4 m306 k

Short-term Borrowings

(38.7 k)

Cash From Financing Activities

4.8 m

Interest Paid

89.4 k

Income Taxes Paid

2.4 k
Y, 2015

Financial Leverage

1.3 x

Adamis Pharmaceuticals Market Value History

Adamis Pharmaceuticals News and Updates

Adamis Pharmaceuticals Company Life and Culture

You may also be interested in